This account of the beginning of the program on laser fusion at Livermore in 1962, and its subsequent development during the decade ending in 1972, was originally prepared as a contribution to the January 1991 symposium 'Achievements in Physics' honoring Professor Keith Brueckner upon his retirement from the University of San Diego at La Jolla. It is a personal recollection of work at Livermore from my vantage point as its scientific leader, and of events elsewhere that I thought significant. This period was one of rapid growth in which the technology of high-power short-pulse lasers needed to drive the implosion of thermonuclear fuel to the temperature and density needed for ignition was developed, and in which the physics of the interaction of intense light with plasmas was explored both theoretically and experimentally.

Nuclear Medicine is the specialty of medical imaging, which utilizes a variety of radionuclides incorporated into specific compounds for diagnostic imaging and therapeutic applications. During recent years, research efforts associated with this discipline have concentrated on the decay characteristics of particular radionuclides and the design of unique radiolabeled tracers necessary to achieve time-dependent molecular images. The specialty is expanding with specific Positron emission tomography (PET) and SPECT radiopharmaceuticals allowing for an extension from functional process imaging in tissue to pathologic processes and nuclide directed treatments. PET is an example of a technique that has been shown to yield the physiologic information necessary for clinical oncology diagnoses based upon altered tissue metabolism. Most PET drugs are currently produced using a cyclotron at locations that are in close proximity to the hospital or academic center at which the radiopharmaceutical will be administered. In November 1997, a law was enacted called the Food and Drug Administration Modernization Act of 1997 which directed the Food and Drug Administration (FDA) to establish appropriate procedures for the approval of PET drugs in accordance with section 505 of the Federal Food, Drug, and Cosmetic Act and to establish current good manufacturing practice requirements for such drugs. At …

The U.S. Department of Energy DOE's Inventions and Innovation (I&I) Program can help if you are an individual inventor or small business planning to develop your energy-saving invention or innovation. The program provides financial assistance at two levels and also offers technical guidance and commercialization support to successful applicants.

Agency strategic plan for the Texas Executive Council of Physical Therapy and Occupational Therapy Examiners describing the organization's planned services, activities, and other goals during fiscal years 2013 through 2017.